Pantoprazole, azithromycin and tinidazole: short duration triple therapy for eradication of Helicobacter pylori infection

Background: Azithromycin is an acid‐stable macrolide that achieves remarkably high concentrations in gastric tissue, persisting above the MIC90 for Helicobacter pylori over a period of 5‐days, after a single 500 mg oral dose. Aim: To evaluate and compare the efficacy, safety, and tolerability of two...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2000-12, Vol.14 (12), p.1613-1617
Main Authors: Calabrese, C., Di Febo, G., Areni, A., Scialpi, C., Biasco, G., Miglioli, M.
Format: Article
Language:English
Subjects:
2-Pyridinylmethylsulfinylbenzimidazoles
Adult
Aged
Azithromycin - administration & dosage
Benzimidazoles - administration & dosage
Biological and medical sciences
Digestive system
Drug Therapy, Combination
Female
Helicobacter Infections - drug therapy
Helicobacter pylori
Humans
Male
Medical sciences
Middle Aged
Omeprazole - analogs & derivatives
Pantoprazole
Pharmacology. Drug treatments
Prospective Studies
Sulfoxides - administration & dosage
Time Factors
Tinidazole - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Azithromycin is an acid‐stable macrolide that achieves remarkably high concentrations in gastric tissue, persisting above the MIC90 for Helicobacter pylori over a period of 5‐days, after a single 500 mg oral dose. Aim: To evaluate and compare the efficacy, safety, and tolerability of two eradicating regimens of pantoprazole, azithromycin and tinidazole. Methods: A total of 100 consecutive symptomatic H. pylori‐positive patients received pantoprazole 40 mg b.d. for 1 week, and were randomly assigned to either azithromycin 500 mg o.m. and tinidazole 500 mg b.d. during the first 3 days (early group, n=50) or during the last 3 days of therapy with pantoprazole (late group, n=50). H. pylori status was assessed by histology and rapid urease test at entry and by histology and 13C‐urea breath test 1 month after the end of the therapy. Results: Ninety‐nine patients completed the study. H. pylori was eradicated in 86% of patients in the early group (intention‐to‐treat 86%) and in 88% of patients in the late group (intention‐to‐treat 88%). Conclusions: This short triple therapy is effective for H. pylori eradication. The compliance was excellent and side‐effects negligible. Moreover, the pantoprazole pre‐treatment did not modify the efficacy of the therapy.
ISSN:0269-2813
1365-2036
DOI:10.1046/j.1365-2036.2000.00879.x